Healthcare May 11, 2022 02:18 PM (GMT+8) · EqualOcean
On May 11, yiouda health learned that Tonghua Guhong Pharmaceutical Co., Ltd. (hereinafter referred to as Tonghua Guhong), a wholly-owned subsidiary of Shandong step Pharmaceutical Co., Ltd. (hereinafter referred to as "step pharmaceutical" or "the company"), announced the termination of the registration procedure of a new drug. It is reported that the name of this new drug is fasudil hydrochloride injection. Its indications are mainly to improve and prevent cerebral vasospasm and subsequent cerebral ischemia after subarachnoid hemorrhage. Step pharmaceutical said that due to the need to further improve the application materials for fasudil hydrochloride injection, Tonghua Guhong applied to the State Drug Administration to withdraw the drug registration application for fasudil hydrochloride injection. Up to now, Tonghua Guhong has invested about 7.6487 million yuan in the R & D cost of fasudil hydrochloride injection.